Global Dopamine Agonist Drug Market - Industry Trends and Forecast to 2026

  • Pharmaceutical
  • Upcoming Report
  • Oct 2019
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Dopamine Agonist Drug Market By Type (Non-Ergoline Dopamine Agonists, Ergot-Derived Dopamine Agonists), Recombinant Factor VIII and Others), Indication (Parkinson's Disease, Restless Leg Syndrome and Others), Drugs (Carbidopa and Levodopa, Ropinirole, Pramipexole, Cabergoline, Bromocriptine and Others), Route of Administration (Oral, Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends and Forecast to 2026

Market Analysis: Global Dopamine Agonist Drug Market

Global dopamine agonist drug market is expected to grow at a substantial CAGR in the forecast period of 2019-2026. Increase in strategic alliances between the pharmaceuticals companies and untapped emerging economies are the key factors that fueling the market growth.

Market Definition: Global Dopamine Agonist Drug Market

Dopamine agonists are the class of drugs that stimulates postsynaptic dopamine receptors directly in the brain. It is most widely used to treat the symptoms of Parkinson’s disease (PD). It works by reducing the motor fluctuations in person with Parkinson’s disease.

Market Drivers

  • Ongoing clinical trial  conducted by many pharmaceuticals industries is propelling the growth of this market
  • Increase in special designation from the regulatory authorities is boosting the market growth
  • High demand of disease specific novel treatment can also act as a market driver
  • The competitive scenario of market and strategic collaborations may boost the market position

Market Restraints

  • Limited operating revenue opportunities for research and development of targeted therapies by many pharmaceuticals is acting as a challenging factor for the growth of this market
  • Low healthcare budget in some developing countries is hamper the market growth
  • Patent expiration of branded drugs and introduction of generics is also hinders the market growth

Segmentation: Global Dopamine Agonist Drug Market

By Type

  • Non-Ergoline Dopamine Agonists
  • Ergot-Derived Dopamine Agonists

By Indication

  • Parkinson's Disease
  • Restless Leg Syndrome
  • Others

By Drugs

  • Carbidopa and Levodopa
  • Ropinirole
  • Pramipexole
  • Cabergoline
  • Bromocriptine
  • Others

By Route of Administration

  • Oral
  • Injectable

By End Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacy

By Geography

  • North America

    • U.S.
    • Canada
    • Mexico

  • South America

    • Brazil
    • Rest of South America

  • Europe

    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Turkey
    • Belgium
    • Netherlands
    • Switzerland
    • Rest of Europe

  • Asia-Pacific

    • Japan
    • China
    • South Korea
    • India
    • Australia
    • Singapore
    • Thailand
    • Malaysia
    • Indonesia
    • Philippines
    • Rest of Asia Pacific

  • Middle East & Africa

    • South Africa
    • Rest of Middle East & Africa

Key Developments in the Market:

  • In June 2019, Intec Pharma Ltd reported results from an earlier phase II trial of Accordion Pill (carbidopa/levodopa) in Parkinson's disease (PD) patients. The trial demonstrated overall PK profile with no adverse event reporting. If trial successful of dopamine agonist, it will change the treatment paradigms for patients suffering from Parkinson’s disease.
  • In January 2019, Alembic Pharmaceuticals Limited received an Abbreviated New Drug Application from the FDA for Pramipexole, extended-release dopamine agonist for the treatment of Parkinson's disease. The FDA approval of pramipexole strengthens the company’s generic portfolio in the therapeutic area of neurology.

Competitive Analysis:

Global dopamine agonist drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares global dopamine agonist drug market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Players:

Few of the major competitors currently working in the global dopamine agonist drug market are GlaxoSmithKline plc, Intas Pharmaceuticals Ltd, Amarin Corporation, Acorda Therapeutics, Inc, US WorldMeds, LLC, Kirin Holdings Company, Limited, UCB S.A., Bausch Health, Boehringer Ingelheim International GmbH, Intec Pharma Ltd, Merck & Co., Inc, Novartis AG, Serina Therapeutics, Apotex Inc, Teva Pharmaceutical Industries Ltd, Mylan N.V., Glenmark Pharmaceuticals Ltd, Torrent Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Dr. Reddy’s Laboratories Ltd, Intec Pharma Ltd and others.

Research Methodology: Global Dopamine Agonist Drug Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons to Purchase this Report

  • Current and future of global dopamine agonist drug market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions